1. Clinical Lymphoma, Myeloma and Leukemia
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence in Situ Hybridization/Cytogenetics: A Real-World Clinical Experience in the Connect CLL Registry 
Anthony Mato, Chadi Nabhan, Neil E. Kay, Nicole Lamanna, Thomas J. Kipps, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Shriya Bhushan, Kristen Sullivan, E. Dawn Flick, Jeff P. Sharman 
Clinical Lymphoma, Myeloma and Leukemia 
DOI: /j.clml
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
Line of Therapy and Genetic Risk-Group Stratification in the Connect CLL Registry. Abbreviations: CLL = chronic lymphocytic leukemia; LOT1 = first line of therapy; LOT≥2 = second or further line of therapy.
Clinical Lymphoma, Myeloma and Leukemia DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
Kaplan–Meier Curves of Event-Free Survival for all Patients Enrolled at (A) LOT1 and (B) LOT≥2, Stratified by Risk. Data Cutoff was August 25, Abbreviations: CI = confidence interval; LOT1 = first line of therapy; LOT≥2 = second or further line of therapy; NR = not reached. (The 15 most frequent regimens are provided in Supplementary Table S3.)
Clinical Lymphoma, Myeloma and Leukemia DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

4. Figure 3
Kaplan–Meier Curves for Event-Free Survival in Unfavorable-Risk and Favorable-Risk Patients at LOT1. (A) Event-Free Survival for Patients Receiving FCR. (B) Event-Free Survival for Patients Receiving BR. Abbreviations: BR = bendamustine and rituximab; CI = confidence interval; FCR = fludarabine, cyclophosphamide, and rituximab; LOT1 = first line of therapy.
Clinical Lymphoma, Myeloma and Leukemia DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions